- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04531163
Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy ((NAC))
Possible Ameliorating Effect of N- Acetylcysteine on Type-II Diabetes Induced Nephropathy
The study is focused on the possible improving effect of N-acetylcysteine on nephropathy of type-2 diabetic patients.
Study design: Prospective clinical based study. The aim of this work is to study the effect of N-acetylcysteine (NAC) on proteinuria and on the serum level of lipoprotein a (LPa) in diabetes induced nephropathy in type-2 diabetic patients.
Study Overview
Status
Intervention / Treatment
Detailed Description
This study will be carried on 60 participants with Type 2 Diabetes with age over 20 years.
Participants will be classified into two groups:
- Group I (Interventional): treated with (NAC) dose of 1200 mg/day for two months in conjunction with conventional treatment.
- Group II (Non-interventional): control group receive conventional treatment.
All patients will undergo the following:
- Full medical history will be taken.
- Laboratory investigations as follows:
Blood samples will be collected for analysis after overnight fasting at the beginning and after 2 months of the study for determination of:
- Total cholesterol (T-chol).
- Plasma triglycerides (TG).
- High density lipoprotein cholesterol (HDL-C).
- Low density lipoprotein cholesterol (LDL-C).
- Fasting blood sugar.
- Blood urea nitrogen (BUN).
- Serum creatinine (SCr).
- Urine analysis.
- Glycated hemoglobin (HbA1c).
- Lipoprotein (a). In addition, blood pressure will be measured for 24 hr.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt, 11651
- Al Azhar University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed diagnosis of Diabetes Mellitus.
- Age over 20 years.
- Patients with proteinuria ≥ 30 mg /dl.
Exclusion Criteria:
- Patients on lipid lowering medications.
- Cigarette smokers.
- Presence of liver and heart diseases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interventional
First arm is experimental, given (NAC) for 2 months in 1200mg/day dosing. Both arms are assigned to pre-treatment analytical tests and post treatment all test analysis are repeated to compare drug effect with placebo group. |
(NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.
Other Names:
|
No Intervention: Non-interventional
Second arm has no intervention.
It is only used to compare results of analytical tests with the first interventional arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lipoprotein (a)
Time Frame: 2 months
|
unique lipoprotein that has emerged as an independent risk factor for developing vascular disease.
|
2 months
|
Triglycerides
Time Frame: 2 months
|
Triglycerides are a type of fat (lipid) found in our blood.
It is one of the lipid panel used to determine atherosclerotic risk that contributes to vascular diseases.
|
2 months
|
Systolic blood pressure
Time Frame: 2 months
|
The first number of blood pressure reading and it indicates how much pressure our blood is exerting against our artery walls when the heart beats.
It is a major risk factor for cardiovascular disease.
|
2 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Huda M. Salem, PhD, AlAzhar university
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Urologic Diseases
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Kidney Diseases
- Diabetic Nephropathies
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Protective Agents
- Respiratory System Agents
- Antioxidants
- Antidotes
- Free Radical Scavengers
- Expectorants
- Acetylcysteine
- N-monoacetylcystine
Other Study ID Numbers
- AlAzharUn
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on N Acetylcysteine
-
Medical University of South CarolinaCompleted
-
Institut d'Anesthesiologie des Alpes MaritimesCompleted
-
Rajavithi HospitalCompletedChemotherapy-induced Peripheral NeuropathyThailand
-
University of Sao Paulo General HospitalActive, not recruiting
-
Indiana UniversityBioAdvantex PharmaCompletedHIV | Endothelial Dysfunction | Oxidative StressUnited States
-
Assaf-Harofeh Medical CenterUnknownChronic Kidney Diseases | General AnesthesiaIsrael
-
Assistance Publique - Hôpitaux de ParisTerminatedSelenoprotein N-related MyopathyFrance
-
VA Office of Research and DevelopmentNational Center for Complementary and Integrative Health (NCCIH)CompletedDiabetic Nephropathy | Proteinuria | Oxidative StressUnited States
-
University of ChicagoNational Institute on Drug Abuse (NIDA); University of MinnesotaCompletedTobacco Use Disorder | GamblingUnited States
-
Universidade Estadual de LondrinaUnknownInflammation | Tobacco Smoking | Oxidative StressBrazil